Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

被引：12

作者：

Bando, Hideaki

Kinoshita, Ichiro

Modi, Shanu

Tsurutani, Junji

Bang, Yung-Jue

Iwata, Hiroji

Sato, Yuta

Nakatani, Shunsuke

Lee, Caleb C.

Sugihara, Masahiro

Okuda, Yasuyuki

Takahashi, Shunji

机构：

[1] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[2] Hokkaido Univ Hosp, Sapporo, Hokkaido, Japan

[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[4] Showa Univ, Tokyo, Japan

[5] Seoul Natl Univ, Coll Med, Seoul, South Korea

[6] Daiichi Sankyo Co Ltd, Tokyo, Japan

[7] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[8] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Med Oncol, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期

关键词：

D O I：

10.1200/JCO.2021.39.15_suppl.6079

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

6079

引用

页数：3

共 50 条

[31] Population Pharmacokinetics of trastuzumab deruxtecan (T-DXd) in HER2positive breast cancer subjects: analyses across 12 Phase 1-3 studies [J].

Li, Claire ;

Henning, Stefanie ;

Patel, Kashyap ;

Hui, Katrina ;

van der Vleuten, Gerly ;

Abutarif, Malaz ;

Garimella, Tushar ;

Khatri, Amit .

CANCER RESEARCH, 2024, 84 (09)

[32] Exceptional responses to pertuzumab, trastuzumab, and docetaxel in human epidermal growth factor receptor-2 high expressing salivary duct carcinomas [J].

Park, Jong Chul ;

Ma, T. Martin ;

Rooper, Lisa ;

Hembrough, Todd ;

Foss, Robert D. ;

Schmitt, Nicole C. ;

Sawhney, Rishi ;

Flanders, Aaron ;

Kang, Hyunseok .

HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2018, 40 (12) :E100-E106

[33] Phase III study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 [J].

Tolaney, S. M. ;

Barroso-Sousa, R. ;

Jiang, Z. ;

Park, Y. H. ;

Rimawi, M. ;

Manich, C. Saura ;

Schneeweiss, A. ;

Toi, M. ;

Yu, T. ;

Shetty, J. ;

Herbolsheimer, P. ;

Loibl, S. .

ANNALS OF ONCOLOGY, 2021, 32 :S507-S508

[34] Phase 3 study of trastuzumab deruxtecan (T-DXd) with or without pertuzumab vs a taxane, trastuzumab and pertuzumab in first-line (1L), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (mBC): DESTINY-Breast09 [J].

Tolaney, Sara M. ;

Barroso-Sousa, Romualdo ;

Jiang, Zefei ;

Park, Yeon Hee ;

Rimawi, Mothaffar ;

Saura, Cristina ;

Schneeweiss, Andreas ;

Toi, Masakazu ;

Yu, Tinghui ;

Shetty, Jagdish ;

Herbolsheimer, Pia ;

Loibl, Sibylle .

CANCER RESEARCH, 2022, 82 (04)

[35] IQGAP1 Protein Binds Human Epidermal Growth Factor Receptor 2 (HER2) and Modulates Trastuzumab Resistance [J].

White, Colin D. ;

Li, Zhigang ;

Dillon, Deborah A. ;

Sacks, David B. .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (34) :29734-29747

[36] A phase 2 trial of trastuzumab deruxtecan (T-DXd, DS-8201) in patients with HER2-positive, unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma [J].

Fuchs, C. ;

Shahidi, J. ;

Mathew, L. ;

Qin, A. ;

Van Cutsem, E. .

ANNALS OF ONCOLOGY, 2020, 31 :S150-S150

[37] Pharmacokinetics, safety, and efficacy of trastuzumab deruxtecan (T-DXd) with OATP1B/CYP3A inhibitors in patients with HER2-expressing advanced solid tumours [J].

Takahashi, M. ;

Bang, Y-J. ;

Karayama, M. ;

Watanabe, J. ;

Minami, H. ;

Yamamoto, N. ;

Kinoshita, I. ;

Lin, C. C. ;

Im, Y-H. ;

Fujiki, T. ;

Achiwa, I. ;

Kamiyama, E. ;

Okuda, Y. ;

Lee, C. ;

Takahashi, S. .

ANNALS OF ONCOLOGY, 2020, 31 :S68-S69

[38] Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study [J].

Vosoughi, Elham ;

Nafissi, Nellie ;

Mahadevan, Aditya ;

Lee, Seungshin ;

Parajuli, Kritisha ;

Rijal, Nejina ;

Parajuli, Ritesh ;

Mehta, Rita S. .

JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

[39] Phase 1/2 study of HER3-DXd in HER3-expressing metastatic breast cancer: Subgroup analysis by HER2 expression [J].

Iwata, Hiroji ;

Krop, Ian E. ;

Masuda, Norikazu ;

Mukohara, Toru ;

Takahashi, Shunji ;

Nakayama, Takahiro ;

Inoue, Kenichi ;

Toyama, Tatsuya ;

Yamamoto, Yutaka ;

Alvarez, Ricardo H. ;

Takahashi, Masato ;

Osaki, Akihiko ;

Ohwada, Shoichi ;

Mostillo, Joseph ;

Tanaka, Yoshimi ;

Sternberg, David ;

Sellami, Dalila .

ANNALS OF ONCOLOGY, 2023, 34 :S1379-S1379

[40] Human Epidermal Growth Factor Receptor 2 (HER2/neu) in Salivary Gland Carcinomas: A Review of Literature [J].

Alotaibi, Abdullah Mislat ;

Alqarni, Mohammed Ali ;

Alnobi, Abdelrahman ;

Tarakji, Bassel .

JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH, 2015, 9 (02) :ZE4-ZE8

← 1 2 3 4 5 →